Teriparatide: A review of its use in osteoporosis

Drugs

Volumn 68, Issue 18, 2008, Pages 2709-2737

  Blick, Stephanie K A ^a,b   Dhillon, Sohita ^a,b   Keam, Susan J ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

Adis drug evaluations; Osteoporosis; Teriparatide, general

Indexed keywords

ALENDRONIC ACID; CALCITONIN; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; ESTROGEN; ETIDRONIC ACID; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; PHOSPHATE; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; VITAMIN D;

ALKALINE PHOSPHATASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTHRALGIA; BONE DENSITY; BONE STRENGTH; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CLINICAL TRIAL; DEPRESSION; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG TOLERABILITY; FATIGUE; FRACTURE; HEADACHE; HOT FLUSH; HUMAN; HYPERCALCEMIA; INJECTION SITE REACTION; INSOMNIA; INSULIN RESISTANCE; LEG CRAMP; LIMB PAIN; MAXIMUM PLASMA CONCENTRATION; MUSCLE SPASM; MYALGIA; NAUSEA; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; OSTEOSARCOMA; PATIENT COMPLIANCE; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; SIDE EFFECT; URIC ACID BLOOD LEVEL; VOMITING;

ANABOLIC AGENTS; COST-BENEFIT ANALYSIS; HUMANS; OSTEOGENESIS; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TERIPARATIDE;

EID: 57749189593     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/0003495-200868180-00012     Document Type: Review

References (96)

1. World Health Organization. Prevention and management of osteoporosis: report of a WHO scientific group. WHO technical report series [online]. Available from URL: http://whqlibdoc.who.int/trs/WHOTRS_921.pdf [Accessed 2008 May 1]
2. European Medicines Agency. Scientific discussion [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/forsteo/659802en6.pdf [Accessed 2008 Apr 3]
3. Francis RM, Aspray TJ, Hide G, et al. Back pain in osteoporotic vertebral fractures. Osteoporos Int 2008; 19 (7): 895-903
4. Lane JM, Serota AC, Raphael B. Osteoporosis: differences and similarities in male and female patients. Orthop Clin North Am 2006 Oct; 37 (4): 601-9
5. Summey BT, Yosipovitch G. Glucocorticoid-induced bone loss in dermatologic patients: an update. Arch Dermatol 2006 Jan; 142 (1): 82-90
6. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007 Nov 15; 357 (20): 2028-39
7. Audran M. Drug combination strategies for osteoporosis. Joint Bone Spine 2006 Jul; 73 (4): 374-8
8. Pfeilschifter J. 2006 DVO-guideline for prevention, diagnosis, and therapy of osteoporosis for women after menopause, for men after age 60 executive summary guidelines. Exp Clin Endocrinol Diabetes 2006 Nov; 114 (10): 611-22
9. Moen MD, Scott LJ. Recombinant full-length parathyroid hormone (1-84). Drugs 2006; 66 (18): 2371-81
10. European Medicines Agency. Teriparatide (Forsteo) 20 μg/80 μL: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/forsteo/H-425-PI-en.pdf [Accessed 2008 Apr 29]
11. Eli Lilly and Company. Forteo™ [teriparatide (rDNA origin)] injection: medical review(s) [online]. Available from URL: http://www.fda.gov/ cder/foi/nda/2002/21-318_FORTEUSO_Prntlbl.pdf [Accessed 2008 Jul 3]
12. Eli Lilly. Forteo™ teriparatide (rDNA) injection 750 μg/3 mL [online]. Available from URL: http://www.fda.gov/cder/foi/label/2008/ 021318s015lbl.pdf [Accessed 2008 Apr 3]
13. Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005; 26 (5): 688-703
14. Brixen KT, Christensen PM, Ejersted C, et al. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paraand digm in the treatment of osteoporosis. Basic Clin Pharmacol Toxicol 2004; 94 (6): 260-70
15. Stroup J, Kane MP, Abu-Baker AM. Teriparatide in the treatment of osteoporosis. Am J Health Syst Pharm 2008 Mar 15; 65 (6): 532-9
16. Girotra M, Rubin MR, Bilezikian JP. The use of parathyroid hormone in the treatment of osteoporosis. Rev Endo Metab Dis 2006; 7 (1-2): 113-21
17. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001 May 10; 344 (19): 1434-41
18. Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003; 18 (1): 9-17
19. Deal C, Omizo M, Schwartz EN, et al. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 2005 Nov; 20 (11): 1905-11
20. Miller PD, Bilezikian JP, Diaz-Curiel M, et al. Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide. J Clin Endocrinol Metab 2007 Sep; 92 (9): 3535-41
21. Center for Drug Evaluation and Research. Medical review(s) [online]. Available from URL: http://www.fda.gov/cder/foi/nda/2002/21-318_FORTEO_Medr_P1. pdf [Accessed 2008 Apr 14]
22. Wermers RA, Recknor CP, Cosman F, et al. Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate. Osteoporos Int 2008; 19 (7): 1055-65
23. Lindsay R, Nieves J, Henneman E, et al. Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(1-34): Kinetics and biochemical response in estrogenized osteoporotic patients. J Clin Endocrinol Metab 1993; 77 (6): 1535-9
24. Cosman F, Dawson-Hughes B, Chen P, et al. Changes in 25-hydroxy-and 1,25-dihydroxyvitamin D during treatment with teriparatide [abstract no. M424]. J Bone Miner Res 2007; 22 Suppl. 1: S210
25. Buxton EC, Yao W, Lane NE. Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34). J Clin Endocrinol Metab 2004 Jul; 89 (7): 3332-6
26. Lindsay R, Cosman F, Zhou H, et al. A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. J Bone Miner Res 2006; 21 (3): 366-73
27. Ma YL, Zeng Q, Donley DW, et al. Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J Bone Miner Res 2006 Jun; 21 (6): 855-64
28. Hurley M, Yao W, Lane NE. Changes in serum fibroblast growth factor 2 in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34). Osteoporos Int 2005 Dec; 16 (12): 2080-4
29. Lindsay R, Cosman F, Zhou H, et al. Prior alendronate treatment does not inhibit the early stimulation of osteoblast activity in response to teriparatide. J Bone Miner Res 2007; 22 Suppl. 1: 124
30. Li J, Burr DB, Stepan JJ, et al. Teriparatide improves bone microarchitecture in postmenopausal women previously treated with alendronate [abstract no. 1095]. J Bone Miner Res 2007 Jan 1; 22 Suppl. 1: S28
31. Dobnig H, Stepan JJ, Burr DB, et al. Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate [abstract no. 1093]. J Bone Miner Res 2007 Jan 1; 22 Suppl. 1: S28
32. Jobke B, Muche B, Burghardt AJ, et al. Teriparatide administration following antiresorptive therapy (BBB-study): changes in 3D microarchitecture, mineralization and remodeling at the iliac crest after 6 months [abstract no. 419]. J Bone Miner Res 2007 Jan 1; 22 Suppl. 1: 127
33. Keaveny TM, Donley DW, Hoffmann PF, et al. Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Miner Res 2007 Jan; 22 (1): 149-57
34. McClung MR, San Martin J, Miller PD, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass [published erratum appears in Arch Intern Med 2005 Oct 10; 165 (18): 2120]. Arch Intern Med 2005 Aug 8; 165 (15): 1762-8
35. Jiang Y, Zhao JJ, Mitlak BH, et al. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003; 18 (11): 1932-41
36. Paschalis EP, Glass EV, Donley DW, et al. Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide. iparatide: new results from the fracture prevention trial. J Clin Endocrinol Metab 2005 Aug; 90 (8): 4644-9
37. Arlot M, Meunier PJ, Boivin G, et al. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 2005 Jul; 20 (7): 1244-53
38. Dobnig H, Sipos A, Jiang Y, et al. Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 2005 Jul; 90 (7): 3970-7
39. Vahle JL, Zuehlke U, Schmidt A, et al. Lack of bone neoplasms and persistence of bone efficacy in cynomolgus macaques following long-term treatment with teriparatide [rhPTH(1-34)]. J Bone Miner Res 2008 Dec; 23 (12): 2033-9
40. Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s) [online]. Available from URL: http://www.fda.gov/ cder/foi/nda/2002/21-318_FORTEO_BioPharmr.pdf [Accessed 2008 Apr 14]
41. Lane NE, Sanchez S, Modin GW, et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis: results of a randomized controlled clinical trial. J Clin Invest 1998 Oct 15; 102 (8): 1627-33
42. Cosman F, Nieves J, Zion M, et al. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 2005 Aug 11; 353 (6): 566-75
43. Cosman F, Nieves J, Woelfert L, et al. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 2001 May; 16 (5): 925-31
44. Finkelstein JS, Leder BZ, Burnett SM, et al. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metab 2006 Aug; 91 (8): 2882-7
45. Lane NE, Sanchez S, Modin GW, et al. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res 2000 May; 15 (5): 944-51
46. Kung AW, Pasion EG, Sofiyan M, et al. A comparison of teriparatide and calcitonin therapy in postmenopausal Asian women with osteoporosis: a 6-month study. Curr Med Res Opin 2006 May; 22 (5): 929-37
47. Hwang JS, Tu ST, Yang TS, et al. Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis. Osteoporos Int 2006; 17 (3): 373-8
48. Genant HK, Halse J, Briney WG, et al. The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Curr Med Res Opin 2005 Jul; 21 (7): 1027-34
49. Miller PD, Schwartz EN, Chen P, et al. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int 2007 Jan; 18 (1): 59-68
50. Prince R, Sipos A, Hossain A, et al. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 2005 Sep; 20 (9): 1507-13
51. Marcus R, Wang O, Satterwhite J, et al. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 2003 Jan; 18 (1): 18-23
52. Genant HK, Siris E, Crans GG, et al. Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index. Bone 2005; 37 (2): 170-4
53. Zanchetta JR, Bogado CE, Ferretti JL, et al. Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 2003; 18 (3): 539-43
54. Boonen S, Marin F, Mellstrom D, et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc 2006 May; 54 (5): 782-9
55. Delmas PD, Licata AA, Reginster JY, et al. Fracture risk reduction during treatment with teriparatide is independent of pre-treatment bone turnover. Bone 2006 Aug; 39 (2): 237-43
56. Gallagher JC, Genant HK, Crans GG, et al. Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. J Clin Endocrinol Metab 2005 Mar; 90 (3): 1583-7
57. Adami S, Martin JS, Munoz-Torres M, et al. Effect of raloxifene after recombinant teriparatide [hPTH (1-34)] treatment in postmenopausal women with osteoporosis. Osteoporos Int 2008 Jan; 19 (1): 87-94
58. Boonen S, Marin F, Obermayer-Pietsch B, et al. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2008 Mar; 93 (3): 852-60
59. Obermayer-Pietsch BM, Marin F, McCloskey EV, et al. Effects of two years of daily teriparatide treatment on bone mineral density in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 2008 May 27; 23 (10): 1591-600
60. Lindsay R, Scheele WH, Neer R, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 2004 Oct 11; 164 (18): 2024-30
61. Minne H, Audran M, Simoes ME, et al. Bone density after teriparatide in patients with or without prior antiresorptive treatment: one-year results from the EUROFORS study. Curr Med Res Opin 2008 Oct 4
62. Eastell R, Hadji P, Farrerons J, et al. Comparison of 3 sequential treatment regimens of teriparatide: final results from the EUROFORS study [abstract no. 1265]. J Bone Miner Res 2006 Sep; 21 Suppl. 1: 70
63. Uusi-Rasi K, Semanick LM, Zanchetta JR, et al. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone 2005; 36 (6): 948-58
64. Chen P, Miller PD, Delmas PD, et al. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res 2006 Nov; 21 (11): 1785-90
65. Cosman F, Wermers RA, Recknor C, et al. Efficacy of adding teriparatide versus switching to teriparatide in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate [abstract no. O423]. J Bone Miner Res 2007; 22 Suppl. 1: 89
66. Chen P, Satterwhite JH, Licata AA, et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 2005 Jun; 20 (6): 962-70
67. Kaufman JM, Orwoll E, Goemaere S, et al. Teriparatide effects Phyon vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 2005 May; 16 (5): 510-6
68. Adachi JD, Hanley DA, Lorraine JK, et al. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study. Clin Ther 2007 Sep; 29 (9): 2055-67
69. Briot K, Ravaud P, Liu-Leage S, et al. Improvement of the persistence with teriparatide in postmenopausal osteoporosis: the French experience of an education program [abstract no. WG36]. J Bone Miner Res 2007 Jan 1; 22 Suppl. 1: 508
70. Arden NK, Earl S, Fisher DJ, et al. Persistence with teriparatide in patients with osteoporosis: the UK experience. Osteoporos Int 2006; 17 (11): 1626-9
71. Fraenkel L, Gulanski B, Wittink D. Patient willingness to take teriparatide. Patient Educ Couns 2007; 65 (2): 237-44
72. Liu H, Michaud K, Nayak S, et al. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis. Arch Intern Med 2006; 166 (11): 1209-17
73. Lundkvist J, Johnell O, Cooper C, et al. Economic evaluation of parathyroid hormone in the treatment of osteoporosis in postmenopausal women. Osteoporos Int 2006 Feb 1; 17 (2): 201-11
74. Pfister AK, Welch CA, Lester MD, et al. Cost-effectiveness strategies to treat osteoporosis in elderly women. South Med J 2006 Feb; 99 (2): 123-31
75. Stevenson M, Jones ML, De Nigris E, et al. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005; 9 (22): 1-160
76. National Institute for Clinical Excellence. Bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptors modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (technology appraisal 87) [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/ TA087guidance.pdf [Accessed 2008 Jul 3]
77. Harper KD, Krege JH, Marcus R, et al. Comments on initial experience with teriparatide in the United States [letter]. Curr Med Res Opin 2006; 22 (10): 1927
78. Anastasilakis A, Goulis DG, Koukoulis G, et al. Acute and chronic effect of teriparatide on glucose metabolism in women with established osteoporosis. Exp Clin Endocrinol Diabetes 2007 Feb; 115 (2): 108-11
79. Sipos A, See K, Rohe M, et al. Antibody response to teriparatide 20 μg: Treatment and follow-up [abstract no. SAT0338]. 2007 Annual European Congress of Rheumatology 2007 Jun 13, 85
80. MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008 Feb 5; 148 (3): 197-213
81. Girotra M, Rubin RR, Bilezikian JP. Anabolic agents for osteoporosis: what is their likely place in therapy? Treatments in Endocrinology 2006; 5 (6): 347-58
82. Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society. Menopause 2006 May 30; 13 (3): 340-67; quiz 368-9
83. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis [online]. Available from URL: http://www.nof.org/ professionals/Clinicians_Guide.htm [Accessed 2008 Jul 21]
84. Qaseem A, Snow V, Shekelle P, et al. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Phyon sicians. Ann Intern Med 2008; 149 (6): 404-15
85. Brown JP, Josse RG, for the Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Can Med Assoc J 2002 Nov 12; 167 Suppl. 10: S1-34
86. National Institute for Health and Clinical Excellence. Osteoporosis - secondary prevention including strontium ranelate: appraisal consultation document (March 2008) [online]. Available from URL: http://www.nice.org.uk/ guidance/index.jsp?action=article&o=40252 [Accessed 2008 Jul 7]
87. Kanis JA, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008 Apr; 19 (4)
88. National Health Service: Clinical Knowledge Summaries. Osteoporosis - treatment [online]. Available from URL: http:// www.prodigy.nhs.uk/ osteoporosis_treatment [Accessed 2008 Jul 7]
89. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003; 349 (13): 1207-15
90. Tashjian Jr AH, Gagel RF. Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res 2006; 21 (3): 354-65
91. Graeff C, Gluer CC, Borggrefe I, et al. Effects of 2 years of teriparatide treatment on bone strength assessed by high resolution CT based finite element analysis of human vertebrae in vivo: results from the EUROFORS study. J Bone Miner Res 2007 Jan 1; 22 Suppl. 1: 323
92. Bodenner D, Redman C, Riggs A. Teriparatide in the management of osteoporosis. Clin Interv Aging 2007; 2 (4): 499-507
93. Ettinger B, San Martin J, Crans G, et al. Differential effects of teriparatide on BMD after treatment with raloxifene or alenable dronate. J Bone Miner Res 2004 May; 19 (5): 745-51
94. Rajzbaum G, Jakob F, Karras D, et al. Characterization of patients in the European Forsteo Observational Study (EFOS): postmenopausal women entering teriparatide treatment in a community setting. Curr Med Res Opin 2008 Feb; 24 (2): 377-84
95. Miller PD, Silverman SL, Gold DL, et al. Rationale, objectives and design of the direct analysis of nonvertebral fracture in the community experience (DANCE) study. Osteoporos Int 2006; 17: 85-90
96. Papaioannou A, Kennedy CC, Dolovich L, et al. Patient adherence to osteoporosis medications. Drugs Aging 2007; 24 (1): 37-55